Liège, Belgium, April 26, 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, announces today that it has signed a partnership agreement with MedinCell for the development of two long-acting injectable products within its Mithra CDMO located in Liège.
The Mithra CDMO offers a wide range of services ranging from early drug development to clinical batches, through the commercial production of complex polymer-based products (vaginal rings, implants) and complex liquid injectables and biologics, both in vials, pre-filled syringes or cartridges.
Based in Montpellier (France), MedinCell is developing a portfolio of long-acting injectable products in different therapeutic areas by combining its BEPO® technology with active ingredients that are already known and marketed. This technology makes it possible to control and guarantee the regular delivery at an optimal therapeutic dose of a drug for several days, weeks or months from the subcutaneous or local injection of a simple, entirely bioresorbable deposit.